In a previous publication1 and in the preceding paper2 we have presented evidence indicating that the serum of newborns with hypoprothrombinemia has a marked deficit of another thromboplastic substance besides PTC. Moreover, in mixture experiments with the thromboplastin generation test and the Loeliger-Koller technique for determination of proconvertin, newborns with severe hypoprothrombinemia appeared to have the same defect as patients receiving prolonged treatment with coumarin compounds. The various deficits of these newborns were corrected by means of stored normal serum.1,2
The recently described Stuart factor3,4 is a stable substance adsorbed by barium sulfate, which participates in the first and probably in the second stage of blood coagulation. Its deficiency is associated with a low thromboplastic activity of the serum and a very prolonged one-stage prothrombin time. The use of Russell viper venom (Stypven) also gives an abnormal result. The determination of proconvertin with a substrate plasma
ABALLÍ AJ, BANÚS VL, de LAMERENS S, ROZENGVAIG S. Coagulation Studies in the Newborn Period: IV. Deficiency of Stuart-Prower Factor as a Part of the Clotting Defect of the Newborn. AMA Am J Dis Child. 1959;97(5_PART_I):549–554. doi:10.1001/archpedi.1959.02070010551003
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: